Alejandra Hernandez-Segura

TL;DR: The molecular regulators of senescence phenotypes and how they are used for identifying senescent cells in vitro and in vivo are described and the importance that these levels of regulations have in the development of therapeutic targets is highlighted.

TL;DR: The heterogeneity of the senescence program is characterized using numerous whole-transcriptome datasets generated by us or publicly available and it is shown that the senescent phenotype is dynamic, changing at varying intervals after senescent induction.

TL;DR: This work focuses on measuring the activity of the lysosomal enzyme Senescence-Associated β-galactosidase (SA-β-gal), the rate of DNA synthesis using 5-ethynyl-2'-deoxyuridine (EdU) incorporation assay, the levels of expression of the cell cycle inhibitors p16 and p21, and the expression and secretion of members of the SenescENCE-Associated Secretory Phenotype (SASP).

TL;DR: To identify new and more stable reference genes in senescent fibroblasts, the Shapiro–Wilk normality test and the coefficient of variation per gene using in public RNAseq datasets were analyzed and the best reference genes to be used universally or in a strain‐dependent manner were defined.

TL;DR: It is found that CDK4/6i‐induced senescent cells do not acquire pro‐tumorigenic and detrimental properties but retain the ability to promote paracrine senescence and undergo clearance, and SASP composition is exquisitely stress‐dependent and a predictor for the biological functions of differentsenescence subsets.